Global Diagnostic Nuclear Medicines Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Diagnostic Nuclear Medicines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Diagnostic Nuclear Medicines include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Diagnostic Nuclear Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Diagnostic Nuclear Medicines, also provides the sales of main regions and countries. Of the upcoming market potential for Diagnostic Nuclear Medicines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diagnostic Nuclear Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Diagnostic Nuclear Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Diagnostic Nuclear Medicines sales, projected growth trends, production technology, application and end-user industry.
Diagnostic Nuclear Medicines Segment by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Medicines Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Medicines Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Diagnostic Nuclear Medicines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diagnostic Nuclear Medicines sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Diagnostic Nuclear Medicines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Diagnostic Nuclear Medicines include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Diagnostic Nuclear Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Diagnostic Nuclear Medicines, also provides the sales of main regions and countries. Of the upcoming market potential for Diagnostic Nuclear Medicines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diagnostic Nuclear Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Diagnostic Nuclear Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Diagnostic Nuclear Medicines sales, projected growth trends, production technology, application and end-user industry.
Diagnostic Nuclear Medicines Segment by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Medicines Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Medicines Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Diagnostic Nuclear Medicines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diagnostic Nuclear Medicines sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Diagnostic Nuclear Medicines Market by Type
- 1.2.1 Global Diagnostic Nuclear Medicines Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Tc-99m
- 1.2.3 F-18
- 1.2.4 Other
- 1.3 Diagnostic Nuclear Medicines Market by Application
- 1.3.1 Global Diagnostic Nuclear Medicines Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Oncology
- 1.3.3 Cardiology
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Diagnostic Nuclear Medicines Market Dynamics
- 2.1 Diagnostic Nuclear Medicines Industry Trends
- 2.2 Diagnostic Nuclear Medicines Industry Drivers
- 2.3 Diagnostic Nuclear Medicines Industry Opportunities and Challenges
- 2.4 Diagnostic Nuclear Medicines Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Diagnostic Nuclear Medicines Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Diagnostic Nuclear Medicines Revenue by Region
- 3.2.1 Global Diagnostic Nuclear Medicines Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Diagnostic Nuclear Medicines Revenue by Region (2020-2025)
- 3.2.3 Global Diagnostic Nuclear Medicines Revenue by Region (2026-2031)
- 3.2.4 Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2020-2031)
- 3.3 Global Diagnostic Nuclear Medicines Sales Estimates and Forecasts 2020-2031
- 3.4 Global Diagnostic Nuclear Medicines Sales by Region
- 3.4.1 Global Diagnostic Nuclear Medicines Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Diagnostic Nuclear Medicines Sales by Region (2020-2025)
- 3.4.3 Global Diagnostic Nuclear Medicines Sales by Region (2026-2031)
- 3.4.4 Global Diagnostic Nuclear Medicines Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Diagnostic Nuclear Medicines Revenue by Manufacturers
- 4.1.1 Global Diagnostic Nuclear Medicines Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Diagnostic Nuclear Medicines Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Diagnostic Nuclear Medicines Sales by Manufacturers
- 4.2.1 Global Diagnostic Nuclear Medicines Sales by Manufacturers (2020-2025)
- 4.2.2 Global Diagnostic Nuclear Medicines Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Diagnostic Nuclear Medicines Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Diagnostic Nuclear Medicines Sales Price by Manufacturers (2020-2025)
- 4.4 Global Diagnostic Nuclear Medicines Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Diagnostic Nuclear Medicines Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Diagnostic Nuclear Medicines Manufacturers, Product Type & Application
- 4.7 Global Diagnostic Nuclear Medicines Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Diagnostic Nuclear Medicines Market CR5 and HHI
- 4.8.2 2024 Diagnostic Nuclear Medicines Tier 1, Tier 2, and Tier 3
- 5 Diagnostic Nuclear Medicines Market by Type
- 5.1 Global Diagnostic Nuclear Medicines Revenue by Type
- 5.1.1 Global Diagnostic Nuclear Medicines Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Diagnostic Nuclear Medicines Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2020-2031)
- 5.2 Global Diagnostic Nuclear Medicines Sales by Type
- 5.2.1 Global Diagnostic Nuclear Medicines Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Diagnostic Nuclear Medicines Sales by Type (2020-2031) & (k units)
- 5.2.3 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2031)
- 5.3 Global Diagnostic Nuclear Medicines Price by Type
- 6 Diagnostic Nuclear Medicines Market by Application
- 6.1 Global Diagnostic Nuclear Medicines Revenue by Application
- 6.1.1 Global Diagnostic Nuclear Medicines Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Diagnostic Nuclear Medicines Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2020-2031)
- 6.2 Global Diagnostic Nuclear Medicines Sales by Application
- 6.2.1 Global Diagnostic Nuclear Medicines Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Diagnostic Nuclear Medicines Sales by Application (2020-2031) & (k units)
- 6.2.3 Global Diagnostic Nuclear Medicines Sales Market Share by Application (2020-2031)
- 6.3 Global Diagnostic Nuclear Medicines Price by Application
- 7 Company Profiles
- 7.1 Bracco Imaging
- 7.1.1 Bracco Imaging Comapny Information
- 7.1.2 Bracco Imaging Business Overview
- 7.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
- 7.1.5 Bracco Imaging Recent Developments
- 7.2 Cardinal Health
- 7.2.1 Cardinal Health Comapny Information
- 7.2.2 Cardinal Health Business Overview
- 7.2.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
- 7.2.5 Cardinal Health Recent Developments
- 7.3 Curium Pharma
- 7.3.1 Curium Pharma Comapny Information
- 7.3.2 Curium Pharma Business Overview
- 7.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
- 7.3.5 Curium Pharma Recent Developments
- 7.4 GE Healthcare
- 7.4.1 GE Healthcare Comapny Information
- 7.4.2 GE Healthcare Business Overview
- 7.4.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
- 7.4.5 GE Healthcare Recent Developments
- 7.5 Jubilant Pharma
- 7.5.1 Jubilant Pharma Comapny Information
- 7.5.2 Jubilant Pharma Business Overview
- 7.5.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
- 7.5.5 Jubilant Pharma Recent Developments
- 7.6 Lantheus
- 7.6.1 Lantheus Comapny Information
- 7.6.2 Lantheus Business Overview
- 7.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
- 7.6.5 Lantheus Recent Developments
- 7.7 SIEMENS
- 7.7.1 SIEMENS Comapny Information
- 7.7.2 SIEMENS Business Overview
- 7.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
- 7.7.5 SIEMENS Recent Developments
- 7.8 Dongcheng
- 7.8.1 Dongcheng Comapny Information
- 7.8.2 Dongcheng Business Overview
- 7.8.3 Dongcheng Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
- 7.8.5 Dongcheng Recent Developments
- 7.9 Eli Lilly
- 7.9.1 Eli Lilly Comapny Information
- 7.9.2 Eli Lilly Business Overview
- 7.9.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
- 7.9.5 Eli Lilly Recent Developments
- 7.10 Novartis
- 7.10.1 Novartis Comapny Information
- 7.10.2 Novartis Business Overview
- 7.10.3 Novartis Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
- 7.10.5 Novartis Recent Developments
- 7.11 China Isotope & Radiation
- 7.11.1 China Isotope & Radiation Comapny Information
- 7.11.2 China Isotope & Radiation Business Overview
- 7.11.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
- 7.11.5 China Isotope & Radiation Recent Developments
- 8 North America
- 8.1 North America Diagnostic Nuclear Medicines Market Size by Type
- 8.1.1 North America Diagnostic Nuclear Medicines Revenue by Type (2020-2031)
- 8.1.2 North America Diagnostic Nuclear Medicines Sales by Type (2020-2031)
- 8.1.3 North America Diagnostic Nuclear Medicines Price by Type (2020-2031)
- 8.2 North America Diagnostic Nuclear Medicines Market Size by Application
- 8.2.1 North America Diagnostic Nuclear Medicines Revenue by Application (2020-2031)
- 8.2.2 North America Diagnostic Nuclear Medicines Sales by Application (2020-2031)
- 8.2.3 North America Diagnostic Nuclear Medicines Price by Application (2020-2031)
- 8.3 North America Diagnostic Nuclear Medicines Market Size by Country
- 8.3.1 North America Diagnostic Nuclear Medicines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Diagnostic Nuclear Medicines Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Diagnostic Nuclear Medicines Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
- 9 Europe
- 9.1 Europe Diagnostic Nuclear Medicines Market Size by Type
- 9.1.1 Europe Diagnostic Nuclear Medicines Revenue by Type (2020-2031)
- 9.1.2 Europe Diagnostic Nuclear Medicines Sales by Type (2020-2031)
- 9.1.3 Europe Diagnostic Nuclear Medicines Price by Type (2020-2031)
- 9.2 Europe Diagnostic Nuclear Medicines Market Size by Application
- 9.2.1 Europe Diagnostic Nuclear Medicines Revenue by Application (2020-2031)
- 9.2.2 Europe Diagnostic Nuclear Medicines Sales by Application (2020-2031)
- 9.2.3 Europe Diagnostic Nuclear Medicines Price by Application (2020-2031)
- 9.3 Europe Diagnostic Nuclear Medicines Market Size by Country
- 9.3.1 Europe Diagnostic Nuclear Medicines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Diagnostic Nuclear Medicines Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Diagnostic Nuclear Medicines Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
- 10 China
- 10.1 China Diagnostic Nuclear Medicines Market Size by Type
- 10.1.1 China Diagnostic Nuclear Medicines Revenue by Type (2020-2031)
- 10.1.2 China Diagnostic Nuclear Medicines Sales by Type (2020-2031)
- 10.1.3 China Diagnostic Nuclear Medicines Price by Type (2020-2031)
- 10.2 China Diagnostic Nuclear Medicines Market Size by Application
- 10.2.1 China Diagnostic Nuclear Medicines Revenue by Application (2020-2031)
- 10.2.2 China Diagnostic Nuclear Medicines Sales by Application (2020-2031)
- 10.2.3 China Diagnostic Nuclear Medicines Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Diagnostic Nuclear Medicines Market Size by Type
- 11.1.1 Asia Diagnostic Nuclear Medicines Revenue by Type (2020-2031)
- 11.1.2 Asia Diagnostic Nuclear Medicines Sales by Type (2020-2031)
- 11.1.3 Asia Diagnostic Nuclear Medicines Price by Type (2020-2031)
- 11.2 Asia Diagnostic Nuclear Medicines Market Size by Application
- 11.2.1 Asia Diagnostic Nuclear Medicines Revenue by Application (2020-2031)
- 11.2.2 Asia Diagnostic Nuclear Medicines Sales by Application (2020-2031)
- 11.2.3 Asia Diagnostic Nuclear Medicines Price by Application (2020-2031)
- 11.3 Asia Diagnostic Nuclear Medicines Market Size by Country
- 11.3.1 Asia Diagnostic Nuclear Medicines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Diagnostic Nuclear Medicines Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Diagnostic Nuclear Medicines Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Diagnostic Nuclear Medicines Market Size by Type
- 12.1.1 SAMEA Diagnostic Nuclear Medicines Revenue by Type (2020-2031)
- 12.1.2 SAMEA Diagnostic Nuclear Medicines Sales by Type (2020-2031)
- 12.1.3 SAMEA Diagnostic Nuclear Medicines Price by Type (2020-2031)
- 12.2 SAMEA Diagnostic Nuclear Medicines Market Size by Application
- 12.2.1 SAMEA Diagnostic Nuclear Medicines Revenue by Application (2020-2031)
- 12.2.2 SAMEA Diagnostic Nuclear Medicines Sales by Application (2020-2031)
- 12.2.3 SAMEA Diagnostic Nuclear Medicines Price by Application (2020-2031)
- 12.3 SAMEA Diagnostic Nuclear Medicines Market Size by Country
- 12.3.1 SAMEA Diagnostic Nuclear Medicines Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Diagnostic Nuclear Medicines Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Diagnostic Nuclear Medicines Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Diagnostic Nuclear Medicines Value Chain Analysis
- 13.1.1 Diagnostic Nuclear Medicines Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Diagnostic Nuclear Medicines Production Mode & Process
- 13.2 Diagnostic Nuclear Medicines Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Diagnostic Nuclear Medicines Distributors
- 13.2.3 Diagnostic Nuclear Medicines Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


